Stock listing
NASDAQ:APRE Aprea Therapeutics, Inc. Stock
Home listing (NASDAQ) of Aprea Therapeutics, Inc.
Follow Aprea Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:APRE
$0.229 USD -0.264 (-53.5%)
Close on Nov 20, 2026
- Day range
- $0.204 – $0.498 USDNov 20, 2026
- Volume
- 2.44M sharesNov 20, 2026
- Market cap
- $3.25M USDAt the close on Nov 20, 2026 · price × 14.19M shares outstanding
- 52-week range
- $0.204 – $1.490 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $259,714 USDMedian day 154,050 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:APRE · Home | $0.229 USD | -0.264 (-53.5%) | 2,440,300 | $0.498 | $0.498 | $0.204 | $0.493 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APRE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.229 | -0.264 | -53.5% | $0.498 | $0.498 | $0.204 | 2,440,300 | |
| $0.493 | +0.028 | +6.0% | $0.461 | $0.500 | $0.451 | 174,000 | |
| $0.465 | +0.012 | +2.6% | $0.443 | $0.485 | $0.443 | 128,300 | |
| $0.453 | +0.047 | +11.6% | $0.395 | $0.486 | $0.390 | 327,200 | |
| $0.406 | -0.010 | -2.4% | $0.429 | $0.460 | $0.400 | 1,646,400 | |
| $0.416 | -0.024 | -5.5% | $0.473 | $0.473 | $0.410 | 94,100 | |
| $0.440 | -0.005 | -1.1% | $0.453 | $0.454 | $0.440 | 149,400 | |
| $0.445 | -0.001 | -0.2% | $0.440 | $0.467 | $0.430 | 74,200 | |
| $0.446 | -0.055 | -11.0% | $0.499 | $0.514 | $0.435 | 158,700 | |
| $0.501 | -0.017 | -3.3% | $0.513 | $0.534 | $0.501 | 90,600 | |
| $0.518 | +0.023 | +4.6% | $0.496 | $0.530 | $0.495 | 65,600 | |
| $0.495 | -0.010 | -2.0% | $0.505 | $0.505 | $0.471 | 140,000 | |
| $0.505 | -0.010 | -1.9% | $0.529 | $0.532 | $0.505 | 20,800 | |
| $0.515 | +0.024 | +4.9% | $0.488 | $0.517 | $0.480 | 63,800 | |
| $0.491 | +0.006 | +1.2% | $0.500 | $0.520 | $0.486 | 89,100 | |
| $0.485 | -0.009 | -1.8% | $0.479 | $0.521 | $0.460 | 167,600 | |
| $0.494 | -0.044 | -8.2% | $0.540 | $0.540 | $0.486 | 171,000 | |
| $0.538 | +0.025 | +4.9% | $0.512 | $0.540 | $0.512 | 147,500 | |
| $0.513 | +0.064 | +14.3% | $0.436 | $0.536 | $0.429 | 187,900 | |
| $0.449 | -0.069 | -13.3% | $0.520 | $0.520 | $0.410 | 568,600 | |
| $0.518 | -0.024 | -4.4% | $0.527 | $0.546 | $0.495 | 89,200 | |
| $0.542 | -0.018 | -3.2% | $0.559 | $0.559 | $0.511 | 130,100 | |
| $0.560 | -0.001 | -0.2% | $0.564 | $0.600 | $0.511 | 81,600 | |
| $0.561 | +0.029 | +5.5% | $0.545 | $0.567 | $0.511 | 366,900 | |
| $0.532 | -0.052 | -8.9% | $0.603 | $0.605 | $0.530 | 201,100 | |
| $0.584 | -0.034 | -5.5% | $0.658 | $0.658 | $0.573 | 160,100 | |
| $0.618 | +0.035 | +6.0% | $0.580 | $0.626 | $0.580 | 65,400 | |
| $0.583 | -0.017 | -2.8% | $0.611 | $0.611 | $0.582 | 74,300 | |
| $0.600 | +0.007 | +1.2% | $0.610 | $0.648 | $0.593 | 136,900 | |
| $0.593 | -0.011 | -1.8% | $0.610 | $0.615 | $0.581 | 116,500 | |
| $0.604 | +0.046 | +8.2% | $0.557 | $0.607 | $0.557 | 70,400 | |
| $0.558 | -0.047 | -7.8% | $0.605 | $0.610 | $0.550 | 239,400 | |
| $0.605 | -0.031 | -4.9% | $0.636 | $0.638 | $0.576 | 249,900 | |
| $0.636 | -0.040 | -5.9% | $0.680 | $0.680 | $0.634 | 198,900 | |
| $0.676 | -0.019 | -2.7% | $0.686 | $0.695 | $0.640 | 296,500 | |
| $0.695 | -0.029 | -4.0% | $0.716 | $0.736 | $0.685 | 862,200 | |
| $0.724 | -0.026 | -3.5% | $0.764 | $0.782 | $0.675 | 779,600 | |
| $0.750 | -0.020 | -2.6% | $0.780 | $0.820 | $0.741 | 581,700 | |
| $0.770 | +0.018 | +2.4% | $0.758 | $0.820 | $0.750 | 591,600 | |
| $0.752 | -0.009 | -1.2% | $0.760 | $0.771 | $0.740 | 69,800 | |
| $0.761 | -0.019 | -2.4% | $0.780 | $0.780 | $0.741 | 53,300 | |
| $0.780 | 0.000 | 0.0% | $0.800 | $0.800 | $0.765 | 52,000 | |
| $0.780 | +0.048 | +6.6% | $0.742 | $0.810 | $0.742 | 282,000 | |
| $0.732 | -0.005 | -0.7% | $0.760 | $0.760 | $0.700 | 189,600 | |
| $0.737 | -0.023 | -3.0% | $0.760 | $0.760 | $0.730 | 96,700 | |
| $0.760 | +0.010 | +1.3% | $0.780 | $0.780 | $0.740 | 80,000 | |
| $0.750 | +0.019 | +2.6% | $0.750 | $0.772 | $0.730 | 117,200 | |
| $0.731 | -0.018 | -2.4% | $0.729 | $0.757 | $0.711 | 186,000 | |
| $0.749 | -0.032 | -4.1% | $0.820 | $0.820 | $0.733 | 184,200 | |
| $0.781 | +0.007 | +0.9% | $0.771 | $0.843 | $0.760 | 120,300 | |
| $0.774 | -0.015 | -1.9% | $0.796 | $0.820 | $0.765 | 127,300 | |
| $0.789 | -0.002 | -0.3% | $0.781 | $0.810 | $0.781 | 61,300 | |
| $0.791 | -0.044 | -5.3% | $0.850 | $0.871 | $0.783 | 134,700 | |
| $0.835 | +0.041 | +5.2% | $0.840 | $0.880 | $0.779 | 317,800 | |
| $0.794 | -0.012 | -1.5% | $0.800 | $0.809 | $0.791 | 89,400 | |
| $0.806 | -0.014 | -1.7% | $0.820 | $0.820 | $0.780 | 111,700 | |
| $0.820 | -0.016 | -1.9% | $0.810 | $0.854 | $0.799 | 168,800 | |
| $0.836 | +0.036 | +4.5% | $0.780 | $0.900 | $0.780 | 462,400 | |
| $0.800 | -0.039 | -4.6% | $0.845 | $0.852 | $0.780 | 476,000 | |
| $0.839 | -0.021 | -2.4% | $0.880 | $0.910 | $0.820 | 344,000 | |
| $0.860 | -0.120 | -12.2% | $0.990 | $0.990 | $0.810 | 1,182,000 | |
| $0.980 | +0.030 | +3.2% | $1.090 | $1.160 | $0.923 | 2,818,700 | |
| $0.950 | +0.145 | +18.0% | $0.815 | $0.990 | $0.802 | 2,148,900 | |
| $0.805 | +0.165 | +25.8% | $0.704 | $0.850 | $0.680 | 2,803,200 | |
| $0.640 | 0.000 | 0.0% | $0.657 | $0.670 | $0.623 | 14,600 | |
| $0.640 | -0.031 | -4.6% | $0.672 | $0.693 | $0.633 | 38,900 |
Splits
1 split · NASDAQ:APRE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:APRE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
Latest deck · Nov 20, 2026
Investor Presentation (November 2026)
Investor deck · 31 slides
Latest news
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
Nov 20, 2026
Closed $0.229 (-53.5%) on Nov 20, 2026
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 5, 2026
Closed $0.518 (+4.6%) on Nov 6, 2026
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Nov 4, 2026
Closed $0.505 (-1.9%) on Nov 4, 2026
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Oct 16, 2026
Closed $0.584 (-5.5%) on Oct 16, 2026
Aprea Therapeutics to Present at October Conferences
Oct 5, 2026
Closed $0.676 (-2.7%) on Oct 5, 2026
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Sep 22, 2026
Closed $0.732 (-0.7%) on Sep 22, 2026
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Aug 28, 2026
Closed $0.839 (-2.4%) on Aug 28, 2026
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $0.683 (+3.5%) on Aug 12, 2026
Aprea Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 99 in all · newest Nov 20, 2026 · oldest 2019
- Decks
- 38 decks · latest Nov 20, 2026
Where Aprea Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:APRE · Home listing · This page | NASDAQ | United States | USD |
| BOATS:APRE | BOATS | United States | USD |
Valuation
Price/book 0.1× against a median of 0.7×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$34.60M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.73
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Liminatus Pharma, Inc. · NASDAQ:LIMN | US$3.37M | US$1.80M | n/a | n/a | n/a | 11.2× | n/a | 4.8× | 0.94 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,063 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.37M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Median of the others | US$3.13M | −US$1.71M | −6.8× | 0.7× | −123.7% | 0.0× | 1.46 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.30 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.39 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Oren Gilad | President and Chief Executive Officer |
| John P. Hamill | Senior Vice President and Chief Financial Officer |
| Brian Wiley | Senior Vice President of Corporate Development & Strategy |
| Eugene Kennedy | Chief Medical Advisor |
| Ze’ev Weiss | Chief Business Advisor |
Board
| Director | Role |
|---|---|
| Bernd R. Seizinger | Director |
| Gabriela Gruia | Director |
| Jean-Pierre Bizzari | Director |
| John B. Henneman | Director |
| Marc Duey | Director |
| Michael Grissinger | Director |
| Rifat Pamukcu | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | −1.9% |
| Q2 2026 | Aug 12, 2026 · Before open | +3.5% |
| Q1 2026 | May 13, 2026 | +4.6% |
| Q4 2025 | Mar 16, 2026 · Before open | +2.7% |
| Q3 2025 | Nov 12, 2025 · Before open | −4.5% |
| Q2 2025 | Aug 12, 2025 · Before open | +0.6% |
| Q1 2025 | May 12, 2025 · Before open | −4.3% |
| Q4 2024 | Mar 25, 2025 · Before open | −3.1% |
| Q3 2024 | Nov 7, 2024 · Before open | −2.6% |
| Q2 2024 | Aug 12, 2024 · Before open | −4.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | +5.4% |
| Q4 2023 | Mar 26, 2024 · Before open | −2.7% |
| Q3 2023 | Nov 9, 2023 · After close | −5.2% |
| Q2 2023 | Aug 10, 2023 · Before open | +2.6% |
| Q1 2023 | May 15, 2023 · After close | +6.2% |
| Q4 2022 | Mar 30, 2023 · After close | −3.5% |
| Q3 2022 | Nov 9, 2022 · After close | −10.9% |
| Q2 2022 | Aug 11, 2022 · After close | −3.9% |
| Q1 2022 | May 16, 2022 · Before open | −19.1% |
| Q4 2021 | Mar 15, 2022 · After close | +14.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 31 slides | Nov 20, 2026 |
| Investor Presentation (November 2026) | Investor deck | 29 slides | Nov 4, 2026 |
| Investor Presentation (August 2026) | Investor deck | 26 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 26 slides | May 13, 2026 |
| Investor Presentation (March 2026) | Investor deck | 28 slides | Mar 30, 2026 |
| Investor Presentation (March 2026) | Investor deck | 27 slides | Mar 16, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 29, 2026 |
| Investor Presentation (January 2026) | Investor deck | 23 slides | Jan 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 20 slides | Nov 12, 2025 |
| Investor Presentation (October 2025) | Investor deck | 21 slides | Oct 15, 2025 |
All 38 decks
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with warrants Announced: about US$5.6M · US$0.89 a share · Warrants at US$0.765 · Maxim Group LLC Dealers: Maxim Group LLC (lead) Insiders: Certain insiders of the Company are among the purchasers Use of proceeds: General corporate purposes and research and development expenses | Jan 29, 2026 |
| Private placement of private placement financing Closed: US$3.1M raised · US$1.165 a share · Warrants at US$1.04 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Insiders: The CEO, the CFO and a Board member participated alongside external investors Use of proceeds: General corporate purposes and research and development expenses | Dec 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Oct 2, 2019.
- Price
- US$15.00 a share
- Shares offered
- 5,666,667 shares of common stock
- Offering size
- US$85 million
- Underwriters' option
- Up to 850,000 more shares
- Listing
- APRE on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Morgan Stanley, RBC Capital Markets · In the order on the cover
- Shares delivered
- On or about Oct 7, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 12, 2019 |
| Filed publicly | Sep 6, 2019 |
| Amended 4 times | Newest Oct 2, 2019 |
| Shares registered with an exchange | Sep 30, 2019 |
| Declared effective by the SEC | Oct 2, 2019 |
| Final prospectus, with the price | Oct 4, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 4, 2019 |
| FWP · Free writing prospectus | Oct 3, 2019 |
| EFFECT · Notice that a registration is effective | Oct 2, 2019 |
| S-1MEF · Registration of more shares for the same offering | Oct 2, 2019 |
| CERT · Exchange's certificate of listing | Oct 2, 2019 |
| S-1/A · Registration statement, amended | Oct 2, 2019 |
| CORRESP · Letter to the SEC | Sep 30, 2019 |
| CORRESP · Letter to the SEC | Sep 30, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 30, 2019 |
| S-1/A · Registration statement, amended | Sep 27, 2019 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 25, 2019 |
| S-1/A · Registration statement, amended | Sep 25, 2019 |
| UPLOAD · Letter from the SEC | Sep 24, 2019 |
| S-1/A · Registration statement, amended | Sep 23, 2019 |
| CORRESP · Letter to the SEC | Sep 16, 2019 |
| S-1 · Registration statement | Sep 6, 2019 |
| DRS/A · Draft registration statement, amended | Aug 20, 2019 |
| DRSLTR · Letter to the SEC with a draft | Aug 20, 2019 |
| UPLOAD · Letter from the SEC | Aug 8, 2019 |
| DRS · Draft registration statement | Jul 12, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 4, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 285.8K | 1.50M | 583.2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 21.7K | 9.36M | 7.05K | 16.4M | 271.7K | 229.6K | 170.3K | 8.32K | 7.93K | 0 |
| Gross profit | 264.0K | -7.86M | 576.2K | -16.4M | -271.7K | -229.6K | -170.3K | -8.32K | -7.93K | 0 |
| Research and development | 7.04M | 9.36M | 7.63M | 16.4M | 23.9M | 37.9M | 21.0M | 14.2M | 13.4M | |
| Selling, general and administrative | 6.48M | 6.46M | 8.43M | 21.0M | 13.6M | 14.9M | 8.59M | 2.29M | 2.46M | 246.5K |
| Operating income | -13.2M | -14.3M | -15.5M | -113.4M | -37.4M | -52.8M | -29.5M | -16.5M | -15.9M | -246.5K |
| Depreciation and amortization | 21.7K | 22.3K | 7.05K | 4.40K | 12.8K | 28.8K | 11.1K | 8.32K | 7.93K | |
| EBITDA | -13.2M | -14.3M | -15.5M | -113.4M | -37.4M | -52.8M | -29.5M | -16.5M | -15.8M | |
| Interest expense | 448.7K | 1.65K | 222.7K | 156.4K | 182 | 15 | 0 | |||
| Income before tax | -12.6M | -13.0M | -14.3M | -112.7M | -37.1M | -53.5M | -28.1M | -15.5M | -15.2M | -436.2K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -12.6M | -13.0M | -14.3M | -112.7M | -37.1M | -53.5M | -28.1M | -15.5M | -15.2M | -436.2K |
| Earnings per share, basic | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 | -4.67 | -13.45 | -13.17 | |
| Earnings per share, diluted | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 | -4.67 | -13.45 | -13.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.6M | 22.8M | 21.6M | 28.8M | 53.1M | 89.0M | 130.1M | 65.7M | 24.4M | |
| Short-term investments | 0 | 0 | ||||||||
| Inventory | 0 | 0 | ||||||||
| Current assets | 15.6M | 23.6M | 22.5M | 30.2M | 56.6M | 92.4M | 133.0M | 66.0M | 24.7M | |
| Property, plant and equipment | 59.8K | 81.5K | 88.4K | 2.32K | 23.9K | 38.5K | 41.6K | 24.4K | 30.3K | |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 15.9M | 24.0M | 22.7M | 30.2M | 56.8M | 92.8M | 133.6M | 66.0M | 24.8M | |
| Accounts payable | 713.7K | 1.35M | 1.67M | 842.8K | 1.77M | 4.50M | 2.18M | 1.74M | 1.66M | 4.22M |
| Current liabilities | 2.76M | 3.36M | 4.39M | 3.20M | 7.32M | 15.3M | 9.06M | 4.87M | 4.30M | 5.70M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 190.5K | 335.2K | 545.0K | |||||||
| Total liabilities | 3.49M | 4.67M | 4.39M | 3.20M | 7.32M | 15.4M | 9.36M | 4.87M | 60.5M | 5.70M |
| Shareholders' equity | 12.4M | 19.3M | 17.0M | 25.6M | 49.5M | 77.4M | 124.2M | -51.4M | -35.8M | |
| Shares outstanding | 8.19M | 5.48M | 3.74M | 2.66M | 1.09M | 21.2M | 21.0M | 1.16M | 21.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.9M | -13.6M | -12.2M | -25.0M | -37.7M | -41.8M | -26.7M | -15.3M | -14.0M | |
| Capital spending | 0 | -15.5K | -93.1K | 0 | 0 | -25.7K | -30.9K | -3.70K | -3.70K | 0 |
| Free cash flow | -12.9M | -13.6M | -12.3M | -25.0M | -37.7M | -41.8M | -26.7M | -15.3M | -14.0M | |
| Cash from investing | -15.5K | -93.1K | -25.7K | -30.9K | -3.70K | -3.70K | ||||
| Cash from financing | 4.64M | 14.8M | 5.14M | 683.0K | 1.75M | 150.9K | 92.6M | 56.4M | 23.3M | |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 92.6M | 56.4M | 23.3M | |||||||
| Change in cash | -8.25M | 1.25M | -7.13M | -24.3M | -35.9M | -41.7M | 65.8M | 41.1M | 9.34M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Jul 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 424B7 · Prospectus | May 15, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 27, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Apr 22, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| 8-K · Current report | Mar 30, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Mar 20, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 17, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 17, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 16, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| UPLOAD · Letter from the SEC | Feb 24, 2026 | Other filings | SEC |
| S-3 · Registration statement | Feb 20, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Current report | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 29, 2025 | Offer document | SEC |
| D | Dec 23, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 23, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 19, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Dec 8, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 17, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 23, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 9, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Aug 21, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 30, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 3, 2024 | Offer document | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2024 | Results | SEC |
| 10-K · Annual report | Mar 26, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 12, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 8, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Feb 5, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Feb 2, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 2, 2024 | Results | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 30, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 26, 2024 | Material contract | SEC |
| S-3 · Registration statement | Jan 26, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Nov 9, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 16, 2023 | Current report | SEC |
| 8-K · Current report | Oct 13, 2023 | Current report | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 24, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 24, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Jul 11, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 11, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 5, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| 4 · Change in ownership | May 8, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 8, 2023 | Insider trade | SEC |
| 8-K · Current report | May 8, 2023 | Management or board change | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2023 | Annual report | SEC |
| 8-K · Current report | Apr 18, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| 4 · Change in ownership | Mar 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Mar 3, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Mar 1, 2023 | Current report | SEC |
This page holds 200 of 447 filings. Open Filings
Cap table
Built by 6ix from Aprea Therapeutics, Inc.’s releases · as of Aug 12, 2026
- Common shares
- 14,191,136
- Fully diluted
- 14,191,136
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 14,191,136 | Aug 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.04 · expire about Dec 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 14,191,136 |
| Aug 12, 2026 | 8,192,538 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael A. Kelly Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Amicus Therapeutics Inc (Director · Since at least Dec 1, 2020); DMC Global Inc. (Director · Since at least Jul 24, 2020); NeoGenomics, Inc. (Board Member · Since at least Jul 15, 2020); Hookipa Pharma Inc (Director · Apr 17, 2019 – Jun 30, 2022 · Past) | Director · Sep 28, 2020 – Jun 30, 2021 · Past |
| Scott M Rocklage Other companies: Pulmatrix, Inc. (Director · Jun 15, 2015 – Feb 3, 2016 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 13, 2018 · Past); EPIRUS Biopharmaceuticals Inc (Director · Jul 15, 2014 – Jun 5, 2015 · Past); Achaogen Inc (Director · Mar 11, 2014 – Mar 11, 2014 · Past); Relypsa Inc (Director · Nov 14, 2013 – Nov 20, 2013 · Past) | Director · Oct 2, 2019 – Jun 30, 2020 · Past |
| Christian S. Schade Other companies: Integra LifeSciences Holdings Corporation (Director · Since at least May 17, 2006); Omega Therapeutics Inc (Director · Jul 10, 2023 – Jun 20, 2024 · Past); Omthera Pharmaceuticals Inc (Executive VP and CFO · Apr 11, 2013 – Jul 16, 2013 · Past); NRG Energy, Inc. (Exec VP & Chief Financial Ofc · Mar 29, 2010 – Mar 29, 2011 · Past) | Director · Oct 2, 2019 – Jul 28, 2022 · Past |
| Jean-Pierre Bizzari Other companies: ADC Therapeutics SA (Non-Executive Director · Since at least Jan 2, 2024); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jan 25, 2020 · Past); Celator Pharmaceuticals Inc (Director · Feb 27, 2015 – Jul 12, 2016 · Past); Halozyme Therapeutics, Inc. (Director · Jan 17, 2015 – May 5, 2023 · Past) | Director · Since at least Aug 23, 2023 |
| Michael Grissinger Other companies: Lipocine Inc. (Director · Since at least Aug 3, 2026); Adicet Bio, Inc. (Director · Since at least Nov 5, 2018); Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past) | Director · Since at least May 16, 2022 |
| Bernd R. Seizinger Other companies: Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); Aptose Biosciences Inc (Director · Sep 13, 2022 – Feb 5, 2024 · Past) | Director · Since at least Oct 2, 2019 |
| Gabriela Gruia Other companies: TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); Molecular Templates Inc (Director · Mar 1, 2022 – Sep 27, 2024 · Past) | Director · Since at least May 5, 2023 |
| John B Henneman III Other companies: Orthofix Medical Inc. (Director · Since at least May 7, 2026); Anika Therapeutics Inc. (Director · Since at least May 1, 2026) | Director · Since at least Jun 16, 2026 |
| John P. Hamill Other companies: Windtree Therapeutics, Inc. (SVP & CFO · Jul 20, 2020 – Jul 26, 2022 · Past); Trevena, Inc. (VP Fin,Princ Fin&Acct Officer · May 31, 2019 – May 31, 2019 · Past) | Senior Vice President and Chief Financial Officer · Since at least Jan 30, 2023 |
| Richard Peters Other companies: Kineta Inc. (Director · Since at least Dec 22, 2020); Merrimack Pharmaceuticals Inc (President and CEO, Director · May 8, 2019 – May 8, 2019 · Past) | Director · Since at least Jun 26, 2020 |
All 24 people
| Person | Seat |
|---|---|
| Eyal C Attar Other companies: Vor Biopharma Inc. (CHIEF MEDICAL OFFICER · Oct 11, 2022 – Feb 13, 2025 · Past) | SVP, Chief Medical Officer, Director · Oct 2, 2019 – Jun 3, 2022 · Past |
| Guido Magni Other companies: Adolor Corp (Director · Jun 6, 2008 – Dec 7, 2011 · Past) | Director · Oct 2, 2019 – Oct 7, 2019 · Past |
| Brian Wiley | Senior Vice President of Corporate Development & Strategy · Since at least Nov 4, 2026 |
| Eugene Kennedy | Chief Medical Advisor · Since at least Oct 16, 2026 |
| Gregory Alan Korbel | SVP, Chief Operating Officer · Oct 2, 2019 – Jul 28, 2022 · Past |
| Gregory S Wessels | SVP, Chief Commercial Officer · Sep 16, 2020 – Feb 25, 2021 · Past |
| John B. Henneman | Director · Since at least Jun 17, 2026 |
| Jonathan Hepple | Director · Oct 2, 2019 – Jun 30, 2020 · Past |
| Lars B Abrahmsen | SVP, Chief Scientific Officer · Oct 2, 2019 – Mar 10, 2022 · Past |
| Marc Duey | Director · Since at least May 16, 2022 |
| Nadeem Q Mirza | Chief Medical Officer · May 1, 2024 – May 1, 2024 · Past |
| Oren Gilad | President and Chief Executive Officer · Since at least Mar 13, 2024 |
| Rifat Pamukcu | Director · Since at least Jun 16, 2026 |
| Ze’ev Weiss | Chief Business Advisor · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Aprea Therapeutics, Inc.